ADCAN Pharma forges strategic partnerships to expand pharmaceutical innovation across the Middle East
The UAE-based pharmaceutical manufacturer has secured five significant licensing and manufacturing agreements with international partners, reinforcing the nation's commitment to advancing healthcare and regional pharmaceutical excellence.
ADCAN Pharma, a distinguished UAE-based pharmaceutical manufacturer, has announced the successful conclusion of five transformative licensing and local manufacturing agreements alongside binding term sheets with esteemed international partners at CPHI Milan 2026, the world’s preeminent pharmaceutical trade exhibition, held from 6th to 8th October 2026.
These strategically significant partnerships, encompassing the therapeutic domains of cardiovascular disease, diabetes, and oncology, are expressly designed to facilitate sophisticated licensing arrangements, facilitate technology transfer, and establish robust local manufacturing collaborations. The agreements represent a meaningful expansion of ADCAN Pharma’s pharmaceutical portfolio whilst simultaneously strengthening pharmaceutical production capabilities throughout the United Arab Emirates, the Kingdom of Saudi Arabia, and the wider Middle Eastern region.
Hamdan Mohamed AlDahmani, Chairman of ADCAN Pharma, articulated the company’s vision with considerable eloquence: “These agreements reflect our focus on building long-term partnerships that can strengthen local manufacturing and expand access to essential medicines. Our priority is to support patient access, capability transfer, and the continued growth of the UAE’s and the region’s pharmaceutical sector.”
Dr Fokion Sinis, Chief Executive Officer of ADCAN Pharma, characterised these memoranda of understanding as integral components of the company’s comprehensive localisation strategy. “Through licensing and technology transfer, we aim to bring critical therapies closer to patients in the UAE whilst strengthening our capabilities across cardiovascular care, diabetes, and oncology across KSA and the Middle East.”
The international partners encompass Elpen, Alvion, and Genepharm of Greece, alongside Inventia of India and Lotus of Taiwan, representing a truly global consortium of pharmaceutical excellence.
Dr. Shaikha Al Mazrouei, Research and Studies Advisor at the Emirates Drug Establishment, emphasised the paramount importance of such collaborative endeavours: “International partnerships in licensing, technology transfer and local manufacturing are an important enabler of the UAE’s pharmaceutical industry. At the EDE, we are committed to ensuring that this growth is supported by a regulatory environment that strengthens quality and compliance, enables innovation and knowledge transfer, and enhances the competitiveness of UAE-manufactured pharmaceutical products in regional and global markets.”
The Emirates Drug Establishment continues to serve as a cornerstone in advancing the nation’s industrial and healthcare priorities, cultivating a regulatory framework that reinforces local pharmaceutical manufacturing excellence, maintains uncompromising quality standards, ensures rigorous compliance, and fosters sustained innovation. This institutional support complements pivotal national initiatives including Make it in the Emirates and the strategic expansion of local production capacity, thereby strengthening domestic manufacturing infrastructure, enhancing patient access to essential therapeutics, and consolidating the UAE’s distinguished position as a preeminent regional hub for pharmaceutical manufacturing and innovation.
Source: WAM